Status:
NOT_YET_RECRUITING
Study of N-homocysteinylation of Key Proteins in Alzheimer's Disease (HO-MA)
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Alzheimer Disease
Eligibility:
All Genders
Phase:
NA
Brief Summary
Alzheimer's disease (AD) is the leading cause of dementia in France. It is a multifactorial pathology, combining genetic and environmental risk factors. Homocysteine, a sulfur-containing amino acid be...
Eligibility Criteria
Inclusion
- age \> 18 years
- Age of onset of AD \< 75 years
- Person with AD with positive CSF biomarkers
- Person who has previously benefited from an analysis of AD genetic characteristics (APP, PSEN1, PSEN2, TREM2, ABCA7, SORL1 genes and ApoE status) and an analysis of monocarbon metabolism genes in the case of biochemical abnormalities by clinical exome, targeted panel or complete exome, and for whom the data set is already available.
Exclusion
- Pregnant, parturient or breast-feeding women
- Minor (not emancipated)
- Person of legal age (subject to a legal protection measure)
- Adult unable to give consent
Key Trial Info
Start Date :
February 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06168955
Start Date
February 1 2024
End Date
December 1 2025
Last Update
January 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Régional Universitaire de Nancy
Nancy, France, 54000